TCE2 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Celldex Therapeutics Inc

Watchlist Manager

Watchlist

Price: 36.02 EUR 2.24% Market Closed

Market Cap: €1.7B

C	Celldex Therapeutics Inc SWB:TCE2	US
Q	Q2 Holdings Inc F:0Q2	US
	Societe BIC SA F:BIF0	FR

Profitability Summary

Celldex Therapeutics Inc's profitability score is 4/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-206 220%

Negative 3Y Average Operating Margin

-24 324%

Declining Operating Margin

-3 720% > -206 220%

Negative Net Margin

-190 221%

Negative 3Y Average Net Margin

-22 255%

Declining Net Margin

-3 470% > -190 221%

Negative Free Cash Flow Margin

-153 231%

Negative 3Y Average Free Cash Flow Margin

-18 074%

Declining Free Cash Flow Margin

-3 506% > -153 231%

Negative ROE

-44%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-423%

Declining ROIC

-267% > -592%

View All

Hide

Collapse

4 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.